MEKTOVI

At a glance

Key dates

1. Approval

   FDA approval date of this drug product.

   Jun 27, 2018

   8 yr 1 mo ago

2. Today

3. Exclusivity ends · I-928

   New indication exclusivity (3 years)

   Oct 11, 2026

   in 4 mo

4. Patent 7777050 expires

   Listed drug substance patent expiration.

   Mar 13, 2027

   in 9 mo

5. Patent 10005761 expires

   Listed method-of-use patent (U-2331) expiration.

   Aug 27, 2030

   in 4 yr 3 mo

6. Patent 10005761 expires

   Listed method-of-use patent (U-3737) expiration.

   Aug 27, 2030

   in 4 yr 3 mo

7. Patent 9850229 expires

   Listed method-of-use patent (U-2333) expiration.

   Aug 27, 2030

   in 4 yr 3 mo

8. Patent 9314464 expires

   Listed method-of-use patent (U-2332) expiration.

   Jul 04, 2031

   in 5 yr 1 mo

9. Patent 9314464 expires

   Listed method-of-use patent (U-3737) expiration.

   Jul 04, 2031

   in 5 yr 1 mo

10. Patent 9562016 expires

    Listed drug substance patent expiration.

    Oct 18, 2033

    in 7 yr 5 mo

11. Patent 9598376 expires

    Listed method-of-use patent (U-2330) expiration.

    Oct 18, 2033

    in 7 yr 5 mo

12. Patent 9980944 expires

    Listed method-of-use patent (U-2334) expiration.

    Oct 18, 2033

    in 7 yr 5 mo

Pharmaceutical detail

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (1)

• I-928New indication exclusivity (3 years)

  Oct 11, 2026

  in 4 mo

Listed patents (9)